Bayer’s Tightrope Walk: Pipeline Promise Meets a $5 Billion Legal Tab

The gap between Bayer’s operational ambition and its financial reality has rarely been wider. On the day of its virtual annual general meeting, the German conglomerate touted strong pharmaceutical sales while simultaneously bracing shareholders for a cash drain of historic proportions. The result? A stock that shed nearly 4% on Friday, sliding to €38.50 and slipping below its 50-day moving average.

Bill Anderson, Bayer’s chief executive, used the shareholder gathering to defend a sweeping restructuring that has already eliminated 14,000 positions since its launch, with 4,700 cuts made in the past year alone. The goal, he argued, is to slash bureaucracy and sharpen operational focus. Yet the numbers tell a story of a company still captive to its past.

Bayer booked a net loss of €3.62 billion for the last fiscal year, driven primarily by multibillion-euro special charges tied to US litigation. Provisions for legal risks now stand at a staggering €11.8 billion. The cash flow outlook is equally grim: management expects negative free cash flow of up to €2.5 billion in 2026, with roughly €5 billion earmarked for ongoing settlement payments.

To preserve liquidity, the board has proposed a minimum dividend of just €0.11 per share for 2025 — a stark signal of financial discipline.

Pharma Pipeline Offers a Counterpoint

Amid the red ink, Bayer’s pharmaceuticals division is delivering a more encouraging narrative. The cancer drug Nubeqa saw sales climb to €2.4 billion, while the heart and kidney treatment Kerendia generated nearly €829 million in revenue. Following expanded regulatory approvals, Bayer sees further upside in both indications.

The company is also preparing to launch Lynkuet, a hormone-free menopause treatment, in the European Union. Anderson is betting that these new products can help offset looming patent expirations on older blockbusters.

Should investors sell immediately? Or is it worth buying Bayer?

Debt reduction is making measurable progress, offering a sliver of financial breathing room. In the agricultural division, Crop Science, the focus remains squarely on profitability. An initiative called the “Modern Ag Alliance” aims to push for uniform US labeling rules and reduce future legal exposure.

Eyes on Washington

The next major inflection point comes on April 27, when the US Supreme Court will hear oral arguments in the “Durnell” glyphosate case. A ruling could potentially halt nationwide lawsuits over missing warning labels. Separately, Bayer is advancing a class-action settlement in Missouri, where a judge has already given preliminary approval to a $7.25 billion deal.

Analysts remain cautiously optimistic. Barclays maintains an “Overweight” rating on Bayer with a €48 price target, citing the fundamental soundness of management’s approach. Charles Pitman-King of Barclays sees a long-term resolution to the glyphosate saga as achievable.

For now, the stock remains highly reactive to headlines. Despite a 72% gain over the past twelve months, short-term volatility is likely to persist. The next scheduled catalyst arrives on May 12, when Bayer reports first-quarter results.

Ad

Bayer Stock: New Analysis - 25 April

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Ad

Bayer Stock: New Analysis - 25 April

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...